Objective To test the reliability and validity of the Chinese version of QLQ-GI.NET21 questionnaire. Methods The researchers obtained the authorization of the original Chinese vision of QLQ-GI.NET21 questionnaire from European Organization for Research on Treatment of Cancer （EORTC）.Then they invited 6 experts to rate the contents of the scale to calculate the content validity index.Then the researchers used the EORTC core quality of life questionnaire (QLQ-C30, version 3.0) and the QLQ-GI.NET21 questionnaire in combination to survey 235 patients with gastrointestinal neuroendocrine tumors.Two weeks later, 60 patients were randomly selected to take part in the second survey. Results A total of 220 respondents completed the first survey, and 46 finished the retest. The Cronbach′s α coefficient was 0.913 for QLQ-GI.NET21, the test-retest reliability coefficient was 0.899,and the content validity index was 0.889. The questionnaire shared a correlation coefficient of 0.417 to QLQ C30 scale （P＜0.01）.Through exploratory analysis, 5 common factors which could explain a cumulative variance of 63.10%, were extracted.The questionnaire could distinguish between patients with metastatic （severe） and non-metastatic （mild） patients regarding each item （P＜0.05）. Conclusion The Chinese version of QLQ-GI.NET21 questionnaire is reliable and valid for measuring quality of life of patients with gastrointestinal neuroendocrine tumors.